From the impact of Obamacare to cutting-edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about a potentially landmark Supreme Court ruling, the impact of President Obama's budget on health-care stocks, the next wave of innovation for the pharma industry, and why investors need to pay attention to a small research company from upstate New York.
In the following segment, health-care analyst David Williamson dives into the legal battle between Myriad Genetics and those who question its ability to patent human genes. The Supreme Court is hearing opening arguments, with a decision expected later this summer.
Watch and discover how far the impact of this verdict could reach.
